SCHEMBL7127939

SCHEMBL7127939

CCOc1c(C(=O)OCc2ccccc2)ccc2c1C(S(=O)(=O)c1ccccc1)CS2(O)O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 4/20 0.41
PRMT5 O14744 1/20 0.41
TDP1 Q9NUW8 3/20 0.37
ALDH1A1 P00352 3/20 0.37
TSHR P16473 3/20 0.37
MAPK1 P28482 2/20 0.37
CYP3A4 P08684 1/20 0.37
CASP3 P42574 1/20 0.37
RAB9A P51151 1/20 0.37
SENP8 Q96LD8 1/20 0.37
SENP7 Q9BQF6 1/20 0.37
SENP6 Q9GZR1 1/20 0.37
POLB P06746 1/20 0.36
KMT2A Q03164 3/20 0.36
SLC6A2 P23975 1/20 0.36
SLC6A3 Q01959 1/20 0.36
MAPT P10636 1/20 0.35
MEN1 O00255 1/20 0.35
HPGD P15428 1/20 0.35
HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7127953 0.92 L3MBTL1 (0.47) L3MBTL1PRMT5TDP1ALDH1A1TSHR
SCHEMBL7127942 0.91 L3MBTL1 (0.41) L3MBTL1PRMT5TDP1ALDH1A1TSHR
SCHEMBL7131227 0.90 ALDH1A1 (0.38) L3MBTL1TDP1ALDH1A1TSHRMAPK1
SCHEMBL7129332 0.90 ALDH1A1 (0.43) L3MBTL1PRMT5TDP1ALDH1A1TSHR
SCHEMBL7125842 0.90 ALDH1A1 (0.43) L3MBTL1PRMT5TDP1ALDH1A1TSHR
SCHEMBL7127700 0.88 KMT2A (0.36) L3MBTL1TDP1ALDH1A1TSHRKMT2A
SCHEMBL7126404 0.87 ACLY (0.33) ALDH1A1TSHRRAB9AKMT2AMAPT
SCHEMBL7133522 0.84 KMT2A (0.40) L3MBTL1ALDH1A1TSHRMAPK1RAB9A
SCHEMBL7127358 0.83 ALDH1A1 (0.44) L3MBTL1TDP1ALDH1A1TSHRMAPK1
SCHEMBL7127957 0.83 L3MBTL1 (0.47) L3MBTL1PRMT5TDP1ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6555555-B1 Inhibitors of interleukin-6 and/or interleukin-12; for example 4,5-dimethyl-1,1-dioxidebenzo(b)thiophene; treating various inflammatory diseases, autoimmune diseases, cancer, osteoporosis ONO PHARMACEUTICAL CO., LTD. (JP) 2003-04-29 US disclosed
US-20030073706-A1 Fused thiophone derivatives and drugs containing the same as the active ingredient KONISHI MIKIO (JP) 2003-04-17 US disclosed
US-6420391-B1 PREVENTION AND/OR TREATMENT OF VARIOUS INFLAMMATORY DISEASES, SEPSIS, MULTIPLE MYELOMA, PLASMA CELL LEUKEMIA, OSTEOPOROSIS, CACHEXIA, PSORIASIS, NEPHRITIS, RENAL CELL CARCINOMA, KAPOSI'S SARCOMA, RHEUMATOID ARTHRITIS, GAMMOPATHY, CASTLEMAN'S ONO PHARMACEUTICAL CO., LTD. (JP) 2002-07-16 US disclosed
EP-1067128-A1 FUSED THIOPHENE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2001-01-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073706-A1 Fused thiophone derivatives and drugs containing the same as the active ingredient TPMT, CD47, THPO L3MBTL1 2967/4885PRMT5 3048/4885TDP1 2238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.